Editas reports positive RUBY trial data: 27/28 SCD patients VOE-free, HbF 48% at month 6

Editas Medicine, Inc.

As of Oct 29, 2024, 28 SCD patients treated; 27 VOE-free post-reni-cel; median follow-up 9.5 months.
Mean total hemoglobin increased from 9.8 g/dL at baseline to 13.8 g/dL at Month 6 (n=18).
Mean HbF percentage reached 48.1% at Month 6; F-cells >90% from Month 4; MCH-F above anti-sickling threshold.
All evaluable patients engrafted; median time to neutrophil engraftment 23 days, platelet 25 days.
Two SAEs possibly related to reni-cel reported; safety consistent with myeloablative conditioning.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Editas Medicine, Inc.: Amended and restated by-laws to clarify definition of 'acting in concert' and make other clarifying changes in accordance with Rule 14a-19 under the Exchange Act (effective 2024-12-06).

Change: bylaw amendment
Effective: 2024-12-06

Exact text from the filing

On December 6, 2024, the Board of Directors of Editas Medicine, Inc. (the “Company”) unanimously adopted Amended and Restated By-Laws of the Company (the “By-Laws”), effective immediately, to clarify the definition of “acting in concert” as used therein, and to make certain other clarifying changes in accordance with Rule 14a-19 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

View on SEC.gov

Browse all governance changes →

Editas Medicine, Inc. filing history →

Source: SEC EDGAR

accession 0001650664-24-000138

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.